NCT05174052View on ClinicalTrials.gov

Dapagliflozin in Patients With Atrial Fibrillation (DAPA-AF)

PHASE3RecruitingINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

June 1, 2022

Primary Completion Date

April 1, 2025

Study Completion Date

April 1, 2025

Conditions
Diabetes MellitusAtrial Fibrillation
Interventions
DRUG

Dapagliflozin 10Mg Tab

Subjects will take 1 blinded tablet of study drug (dapagliflozin 10 mg) dosed once daily.

DRUG

Placebo

Subjects will take 1 blinded capsule of placebo drug dosed once daily

Trial Locations (1)

73104

RECRUITING

University of Oklahoma Health Sciences Center, Oklahoma City

All Listed Sponsors
lead

University of Oklahoma

OTHER